Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.

Clin Genitourin Cancer 2019 04 5;17(2):e263-e272. Epub 2018 Dec 5.

Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Electronic address:

Background: Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known.

Patients And Methods: A retrospective database of patients with metastatic renal cell carcinoma (RCC) treated at University of Texas Southwestern Medical Center between 2006 and 2015 was created. Data relevant to their diagnosis, treatment course, and outcomes were systematically collected. Survival was analyzed by the Kaplan-Meier method. Patients with BM were compared with patients without BM after adjusting for the timing of BM diagnosis, either prior to or during first-line systemic therapy. The impact of stratification according to IMDC risk group was assessed.

Results: A total of 56 (28.4%) of 268 patients with metastatic RCC were diagnosed with BM prior to or during first-line systemic therapy. Median overall survival (OS) for systemic therapy-naive patients with BM compared with matched patients without BM was 19.5 versus 28.7 months (P = .0117). When analyzed according to IMDC risk group, the median OS for patients with BM was similar for favorable- and intermediate-risk patients (not reached vs. not reached; and 29.0 vs. 36.7 months; P = .5254), and inferior for poor-risk patients (3.5 vs. 9.4 months; P = .0462). For patients developing BM while on first-line systemic therapy, survival from the time of progression did not significantly differ by presence or absence of BM (11.8 vs. 17.8 months; P = .6658).

Conclusions: Survival rates for patients with BM are significantly better than historical reports. After adjusting for systemic therapy, the survival rates of patients with BM in favorable- and intermediate-risk groups were remarkably better than expected and not statistically different from patients without BM, though this represents a single institution experience, and numbers are modest.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534272PMC
April 2019
25 Reads
1.693 Impact Factor

Publication Analysis

Top Keywords

systemic therapy
20
patients
16
months p =
16
patients metastatic
12
first-line systemic
12
imdc risk
12
risk group
8
survival rates
8
therapy survival
8
metastatic renal
8
survival outcomes
8
prior first-line
8
favorable- intermediate-risk
8
renal cell
8
patients favorable-
8
cell carcinoma
8
rates patients
8
patients compared
8
adjusting systemic
8
kidney cancer
8

Similar Publications